Literature DB >> 16004855

Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis.

Edith A Nutescu1, Cathy M Helgason.   

Abstract

Atrial fibrillation is a common cardiac arrhythmia and the leading risk factor for stroke. In those at moderate to high risk of stroke, oral anticoagulation therapy with warfarin (a vitamin K antagonist) significantly reduces not only the frequency of such events but also their severity and the associated risk of death. However, achieving optimal anticoagulation with this agent is clinically challenging in view of its complex pharmacokinetic and pharmacodynamic profile. In this regard, concomitant drug therapy (both prescription and over-the-counter medications, including herbal products, vitamins, and various nutritional supplements), along with alcohol intake, dietary factors, and changes in lifestyle, can significantly affect anticoagulation control and thereby expose patients to the risk of bleeding or thromboembolic complications (due to over- and underanticoagulation, respectively). Therefore, it is recommended that intensified monitoring of anticoagulation be performed at initiation and discontinuation of concomitant drug therapy, and in the case of significant dietary and lifestyle changes. Moreover, many patients receive inadequate education and are unaware of such risks and their implications, highlighting the need for better awareness and education on this important aspect of anticoagulation therapy.

Entities:  

Year:  2005        PMID: 16004855     DOI: 10.1007/s11936-005-0052-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  62 in total

Review 1.  Managing oral anticoagulant therapy.

Authors:  J Ansell; J Hirsh; J Dalen; H Bussey; D Anderson; L Poller; A Jacobson; D Deykin; D Matchar
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation.

Authors:  Patricia A Howard; Edward F Ellerbeck; Kimberly K Engelman; Kelly L Patterson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Oct-Nov       Impact factor: 2.890

3.  American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.

Authors:  Jack Hirsh; Valentin Fuster; Jack Ansell; Jonathan L Halperin
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

4.  Acetaminophen and warfarin: undesirable synergy.

Authors:  W R Bell
Journal:  JAMA       Date:  1998-03-04       Impact factor: 56.272

5.  Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy.

Authors:  M Naganuma; T Shiga; K Nishikata; T Tsuchiya; H Kasanuki; E Fujii
Journal:  J Cardiovasc Pharmacol Ther       Date:  2001-10       Impact factor: 2.457

6.  Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.

Authors:  Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

7.  Investigations of the effects of ethanol on warfarin binding to human serum albumin.

Authors:  C E Ha; C E Petersen; D S Park; K Harohalli; N V Bhagavan
Journal:  J Biomed Sci       Date:  2000 Mar-Apr       Impact factor: 8.410

8.  No clinically relevant drug interaction between paracetamol and phenprocoumon based on a pharmacoepidemiological cohort study in medical inpatients.

Authors:  Karin Fattinger; Roberto Frisullo; Urspeter Masche; Suzanne Braunschweig; Peter J Meier; Malgorzata Roos
Journal:  Eur J Clin Pharmacol       Date:  2002-02       Impact factor: 2.953

9.  Anticoagulation to prevent stroke in atrial fibrillation and its implications for managed care.

Authors:  D E Singer
Journal:  Am J Cardiol       Date:  1998-03-12       Impact factor: 2.778

10.  Co-ingestion of herbal medicines and warfarin.

Authors:  Lindsay Smith; Edzard Ernst; Patrick Myers; Calli Smith
Journal:  Br J Gen Pract       Date:  2004-06       Impact factor: 5.386

View more
  1 in total

1.  Monitoring of anticoagulant therapy in heart disease: considerations for the current assays.

Authors:  Mohammadali Boroumand; Hamidreza Goodarzynejad
Journal:  J Tehran Heart Cent       Date:  2010-05-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.